Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AlloGraf
- Development stage
- Preclinical
- Lead developer
- Serina Therapeutics
- Modality
- Cell Therapies
- Administration
- Topical
01
Overview
**AlloGraf** is an investigational, universal, permanently engrafting and immune-tolerant bilayered living human skin equivalent developed by Escape Therapeutics for partial thickness wounds. The product incorporates Escape's MorphoGel scaffold with PluraStem-derived fibroblasts and epidermal progenitors in a defined animal-free protein and/or synthetic biocompatible polymer matrix, with the aim of providing an off-the-shelf skin-replacement therapy usable across HLA types without HLA matching or adjunctive immunosuppression. ([escapetherapeutics.com](https://www.escapetherapeutics.com/allograf.html))
- Other names
- AlloGraf
Beyond the preview
Go deeper on AlloGraf.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlloGraf.